Difference between revisions of "Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
 
 
Line 1: Line 1:
 
{{infobox_publicationsection}}
 
{{infobox_publicationsection}}
−
<b>From publication:</b> "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)" in the journal Emerg Microbes Infect (2020)<br> https://doi.org/10.1080/22221751.2020.1735265<br><h3><u>Section 3.5.3: Antiviral treatment</u></h3><b><em>Go to [[Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265) (from DOI: 10.1080/22221751.2020.1735265)|next section]] in publication</em></b><p>Currently, there is no evidence to support the effectiveness of existing antiviral drugs against SARS-CoV-2. Lopinavir/ritonavir can be used when appropriate, 2 tablets, twice daily for 14 days.</p><small><b><em>Go to [[Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)|next section]] in publication</em></b></small>
+
<b>From publication:</b> "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)" in the journal Emerg Microbes Infect (2020)<br> https://doi.org/10.1080/22221751.2020.1735265<br><h3><u>Section 3.5.3: Antiviral treatment</u></h3><p>Currently, there is no evidence to support the effectiveness of existing antiviral drugs against SARS-CoV-2. Lopinavir/ritonavir can be used when appropriate, 2 tablets, twice daily for 14 days.</p><small><b><em>Go to [[Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)|next section]] in publication</em></b></small>

Latest revision as of 19:09, 14 May 2020


Navigation
ArticleDiagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0) (DOI: 10.1080/22221751.2020.1735265)
Sections in this Publication
SectionSection 1: Introduction (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265)
SectionSection 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265)
Named Entities in this Section

From publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)" in the journal Emerg Microbes Infect (2020)
https://doi.org/10.1080/22221751.2020.1735265

Section 3.5.3: Antiviral treatment

Currently, there is no evidence to support the effectiveness of existing antiviral drugs against SARS-CoV-2. Lopinavir/ritonavir can be used when appropriate, 2 tablets, twice daily for 14 days.

Go to next section in publication

Retrieved from "http://wikibase.slis.ua.edu/w/index.php?title=Section_3.5.3:_Antiviral_treatment_(from_DOI:_10.1080/22221751.2020.1735265)&oldid=193764"